Opiant is a specialty pharmaceutical company developing medicines for addiction and drug overdose. The Company developed NARCANÂŽ (naloxone hydrochloride) Nasal Spray (âNARCANÂŽâ), a treatment to reverse opioid overdose. This product was conceived and developed by the Company, licensed to Adapt Pharma Operations Limited (âAdaptâ), an Ireland based pharmaceutical company in December 2014 and approved by the U.S. Food and Drug Administration (âFDAâ) in November 2015. It is marketed by Adapt. In October 2018, Emergent BioSolutions, Inc. ("EBS") completed its acquisition of Adapt. The Company's current pipeline includes medicines in development for Opioid Overdose Reversal (âOORâ), Alcohol Use Disorder (âAUDâ), Opioid Use Disorder (âOUDâ), and Acute Cannabinoid Overdose (âACOâ). The Company is also pursuing other treatment opportunities within the addiction and drug overdose field. Source
No articles found.
NuvectraÂŽ is a neurostimulation company committed to helping physicians improve t...
NuvectraÂŽ is a neurostimulation company commit...
Cue Biopharma is an innovative clinical stage immunotherapy company developing a n...
Cue Biopharma is an innovative clinical stage i...
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on develop...
Cara Therapeutics is a clinical-stage biopharma...
Gamida Cell is a clinical-stage biopharmaceutical company committed to developing ...
Gamida Cell is a clinical-stage biopharmaceutic...
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the ...
Moleculin Biotech, Inc. is a clinical stage pha...
MediciNova, Inc. is a publicly-traded biopharmaceutical company focused on acquiri...
MediciNova, Inc. is a publicly-traded biopharma...
We exist to make the first step in a familys path to recovery the right step thro...
We exist to make the first step in a familys p...
Join the National Investor Network and get the latest information with your interests in mind.